DeFazio A - Search Results

1

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.

Burdett NL, Willis MO, Pandey A, Fereday S; AOCS Study Group; DeFazio A, Bowtell DDL, Christie EL. Burdett NL, et al. Among authors: defazio a. Sci Rep. 2023 Dec 11;13(1):21884. doi: 10.1038/s41598-023-48153-x. Sci Rep. 2023. PMID: 38072854 Free PMC article.

2

Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines.

deFazio A, Chiew YE, Donoghue C, Lee CS, Sutherland RL. deFazio A, et al. J Biol Chem. 1992 Sep 5;267(25):18008-12. J Biol Chem. 1992. PMID: 1517234 Free article.

3

Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells.

deFazio A, Chiew YE, McEvoy M, Watts CK, Sutherland RL. deFazio A, et al. Cell Growth Differ. 1997 Aug;8(8):903-11. Cell Growth Differ. 1997. PMID: 9269899

4

Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines.

deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. deFazio A, et al. Int J Cancer. 2000 Aug 15;87(4):487-98. Int J Cancer. 2000. PMID: 10918187 Free article.

5

Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.

Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A. Davis T, et al. Among authors: defazio a. Clin Cancer Res. 2000 Nov;6(11):4334-42. Clin Cancer Res. 2000. PMID: 11106251

6

Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.

Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL. Arnett-Mansfield RL, et al. Among authors: defazio a. Cancer Res. 2001 Jun 1;61(11):4576-82. Cancer Res. 2001. PMID: 11389093

7

Cell proliferation in the normal mouse mammary gland and inhibition by phenylbutyrate.

Kennedy C, Byth K, Clarke CL, deFazio A. Kennedy C, et al. Among authors: defazio a. Mol Cancer Ther. 2002 Oct;1(12):1025-33. Mol Cancer Ther. 2002. PMID: 12481425

8

Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors.

Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC; Australian Cancer Study Group; Australian Ovarian Cancer Study Group. Nagle CM, et al. Eur J Cancer. 2008 Nov;44(16):2477-84. doi: 10.1016/j.ejca.2008.07.009. Epub 2008 Aug 15. Eur J Cancer. 2008. PMID: 18707869

9

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group. Lose F, et al. J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28. J Natl Cancer Inst. 2008. PMID: 18957670

10

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ; AOCS Study Group; deFazio A, Chenevix-Trench G, Bowtell DD. Anglesio MS, et al. Among authors: defazio a. Mol Cancer Res. 2008 Nov;6(11):1678-90. doi: 10.1158/1541-7786.MCR-08-0193. Mol Cancer Res. 2008. PMID: 19010816 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page